Retreatment by antithymocyte globulin for second kidney transplantation: Efficacy, tolerance and safety

Rodriguez-Reimundes, E.; Buron, Fanny; Chauvet, C.; Daoud, S.; Thaunat, Olivier; Brunet, M.; Badet, Lionel; Morélon, Emmanuel

doi:10.1016/j.trim.2012.11.008

Cited by 5 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent retrospective case-control series also indicated that in patients undergoing a second kidney transplant, rATG induction achieves similar lymphocyte depletion to that observed after a first course, and is as well tolerated [ 98 ]. In pediatric kidney transplant recipients, good outcomes have been reported with rATG at a dose of 1.5–2.5 mg/kg/day for 5–10 days [ 99 – 103 ], with promising rates of graft survival in high-risk patients, but dose-finding studies and robust comparisons with other regimens are lacking.…”

Section: Ratg In Kidney Transplantationmentioning

confidence: 99%

New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity

Mohty

Bacigalupo

Saliba

et al. 2014

Drugs

Self Cite

View full text Add to dashboard Cite

In the 30 years since the rabbit antithymocyte globulin (rATG) Thymoglobulin® was first licensed, its use in solid organ transplantation and hematology has expanded progressively. Although the evidence base is incomplete, specific roles for rATG in organ transplant recipients using contemporary dosing strategies are now relatively well-identified. The addition of rATG induction to a standard triple or dual regimen reduces acute cellular rejection, and possibly humoral rejection. It is an appropriate first choice in patients with moderate or high immunological risk, and may be used in low-risk patients receiving a calcineurin inhibitor (CNI)-sparing regimen from time of transplant, or if early steroid withdrawal is planned. Kidney transplant patients at risk of delayed graft function may also benefit from the use of rATG to facilitate delayed CNI introduction. In hematopoietic stem cell transplantation, rATG has become an important component of conventional myeloablative conditioning regimens, following demonstration of reduced acute and chronic graft-versus-host disease. More recently, a role for rATG has also been established in reduced-intensity conditioning regimens. In autoimmunity, rATG contributes to the treatment of severe aplastic anemia, and has been incorporated in autograft projects for the management of conditions such as multiple sclerosis, Crohn’s disease, and systemic sclerosis. Finally, research is underway for the induction of tolerance exploiting the ability of rATG to induce immunosuppresive cells such as regulatory T-cells. Despite its long history, rATG remains a key component of the immunosuppressive armamentarium, and its complex immunological properties indicate that its use will expand to a wider range of disease conditions in the future.

show abstract

Section: Ratg In Kidney Transplantationmentioning

confidence: 99%